ILUMYA DOSING & ADMINISTRATION

ILUMYA® IS DOSED 4 TIMES A YEAR AFTER 2 INITIAL INJECTIONS1

Could your patients who struggle with self-injection benefit from quarterly in-office dosing?

ILUMYA® IS DOSED 4 TIMES A YEAR AFTER 2 INITIAL INJECTIONS1

Could your patients who struggle with self-injection benefit from quarterly in-office dosing?

Medical_ICON

HEALTHCARE PROFESSIONAL ADMINISTRATION

Prescribing ILUMYA® (tildrakizumab-asmn) helps you stay in control of dosing with in-office administration and oversight of patients who struggle with treatment compliance and comorbidities.1,2

Gas_ICON

1 DOSE = ONE 100 mg/mL INJECTION

The 100 mg dose of ILUMYA® is recommended for all patients, regardless of weight.1

Treatment options for adults with moderate-to-severe plaque psoriasis*

This graphic is not intended to compare the efficacy or safety of the treatments shown here. Additional considerations, aside from the dosing profile, should be taken into account before making a treatment decision. For complete product information, refer to each product’s Prescribing Information.

*Indications and dosage information accessed November 2021. For complete product information, including current indications and dosing, refer to each product’s Prescribing Information.

†Administered as one 150 mg single-dose prefilled pen or syringe, or two 75 mg prefilled syringes.

‡Reflects adult dosing. For some adult patients, a dose of 150 mg may be acceptable.

§Reflects adult dosing.

Indicated trademarks are registered trademarks of their respective owners.

Skyrizi® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Tremfya® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Cosentyx® is indicated for the treatment of moderate-to-severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.

Taltz® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Humira® is indicated for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Humira® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Otezla® is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Administering ILUMYA® (tildrakizumab-asmn)1

Administration Step 1: Waiting Clock Icon

1

Let the ILUMYA® carton sit at room temperature for at least 30 minutes before injecting.

Administration Step 2: Injection Site Body Icon

2

Choose an injection site with clear skin and easy access (such as the abdomen, thigh, or upper arm).

Administration Step 3: Tildrakizumab Syringe Icon

3

Inject the full amount (1 mL), which provides 100 mg of tildrakizumab per syringe.

Administration Step 4: Hazardous Waste Bucket Icon

4

Discard the syringe after use.

Watch a healthcare professional (Dr. George Han) follow step-by-step instructions to properly inject ILUMYA® into a real patient.

Storage Calendar Icon

ROOM TEMPERATURE STABILITY CAN ALLOW FOR STORAGE FLEXIBILITY1

ILUMYA® should be refrigerated. 30 minutes before injecting, let ILUMYA® sit at room temperature. Once stored at room temperature, do not place back in the refrigerator. However, 30-day room temperature stability means ILUMYA® can be administered later if your patient misses their appointment.

5 YEARS OF LASTING CLEARANCE9

ILUMYA® minimized measurable disease
over 5 years of continuous treatment9

Explore Efficacy

5 YEARS OF CONSISTENT SAFETY DATA1,9

Consistent rates of adverse events over 5 years
of continuous clinical studies1.9

SEE 5-YEAR SAFETY

INDICATION AND IMPORTANT SAFETY INFORMATION

ILUMYA® (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

CONTRAINDICATIONS

ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity

Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.

Infections

ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves.

Pretreatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment.

Immunizations

Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.

Adverse Reactions

The most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.

Please see full Prescribing Information.

 

References: 1. ILUMYA® [package insert]. Princeton, NJ: Sun Pharmaceutical Industries, Inc. 2. Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367. 3. Skyrizi® (risankizumab-rzaa) [package insert]. North Chicago, IL: AbbVie Inc. 4. Tremfya® (guselkumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 5. Cosentyx® (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 6. Taltz® (ixekizumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company. 7. Humira® (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc. 8. Otezla® (apremilast) [package insert]. Thousand Oaks, CA: Amgen Inc. 9. Thaçi D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185(2):323-334.